WO2017219029A2 - Compositions and methods for the depletion of cd117+cells - Google Patents

Compositions and methods for the depletion of cd117+cells Download PDF

Info

Publication number
WO2017219029A2
WO2017219029A2 PCT/US2017/038158 US2017038158W WO2017219029A2 WO 2017219029 A2 WO2017219029 A2 WO 2017219029A2 US 2017038158 W US2017038158 W US 2017038158W WO 2017219029 A2 WO2017219029 A2 WO 2017219029A2
Authority
WO
WIPO (PCT)
Prior art keywords
optionally substituted
antibody
antigen
binding fragment
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2017/038158
Other languages
English (en)
French (fr)
Other versions
WO2017219029A3 (en
WO2017219029A8 (en
Inventor
Andrew Nixon
Dwight Morrow
Adam Hartigan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dianthus Therapeutics Inc
Original Assignee
Magenta Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to EP17814263.4A priority Critical patent/EP3472178A4/en
Priority to CA3028134A priority patent/CA3028134A1/en
Priority to CN201780050606.8A priority patent/CN109661400A/zh
Priority to KR1020237014621A priority patent/KR20230066647A/ko
Priority to MX2018015684A priority patent/MX2018015684A/es
Priority to IL303455A priority patent/IL303455A/en
Priority to IL263744A priority patent/IL263744B2/en
Priority to SG11201811290VA priority patent/SG11201811290VA/en
Priority to EA201892659A priority patent/EA201892659A1/ru
Application filed by Magenta Therapeutics Inc filed Critical Magenta Therapeutics Inc
Priority to JP2019518186A priority patent/JP7062647B2/ja
Priority to BR112018076306-3A priority patent/BR112018076306A2/pt
Priority to KR1020197001540A priority patent/KR20190038537A/ko
Publication of WO2017219029A2 publication Critical patent/WO2017219029A2/en
Publication of WO2017219029A3 publication Critical patent/WO2017219029A3/en
Anticipated expiration legal-status Critical
Publication of WO2017219029A8 publication Critical patent/WO2017219029A8/en
Priority to JP2022069352A priority patent/JP2022106807A/ja
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
    • A61K47/6809—Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6829—Bacterial toxins, e.g. diphteria toxins or Pseudomonas exotoxin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6831—Fungal toxins, e.g. alpha sarcine, mitogillin, zinniol or restrictocin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • the invention thus provides methods of treating a variety of hematopoietic conditions, such as sickle cell anemia, thalassemia, Fanconi anemia, Wiskott-Aldrich syndrome, adenosine deaminase deficiency-severe combined immunodeficiency, metachromatic leukodystrophy, Diamond-Blackfan anemia and Schwachman-Diamond syndrome, human immunodeficiency virus infection, and acquired immune deficiency syndrome, as well as cancers and autoimmune diseases, among others.
  • hematopoietic conditions such as sickle cell anemia, thalassemia, Fanconi anemia, Wiskott-Aldrich syndrome, adenosine deaminase deficiency-severe combined immunodeficiency, metachromatic leukodystrophy, Diamond-Blackfan anemia and Schwachman-Diamond syndrome, human immunodeficiency virus infection, and acquired immune deficiency syndrome, as well as cancers and autoimmune diseases
  • the CD1 17 is GNNK+
  • the invention features a method, for example, of treating a human patient in need of a hematopoietic stem cell transplant, including: administering to a human patient a ligand or fragment thereof capable of binding CD1 17 in an amount sufficient to deplete a population of CD1 17+ cells in the patient, and subsequently administering to the patient a transplant including hematopoietic stem cells.
  • RA and RB together with the oxygen atoms to which they are bound, combine to form an optionally substituted 5-membered heterocyclolalkyl group
  • Rs is OH, NH 2 , ORc, ORD, NHRC, or NRCRD;
  • Z is a chemical moiety formed from a coupling reaction between a reactive substituent present on L and a reactive substituent present within an antibody, antigen-binding fragment thereof, or ligand that binds CD1 17 (such as GNNK+ CD1 17);
  • Re is H, OH, ORc, ORD, RC, or RD;
  • R 9 is H or OH ;
  • Rc is as defined above.
  • the method is used to treat an autoimmune disease, such as by administration of an antibody, antigen- binding fragment thereof, or ligand so as to deplete a population of CD1 17+ autoimmune cells and/or by administration of an antibody, antigen-binding fragment thereof, or ligand so as to deplete a population of endogenous hematopoietic stem cells prior to hematopoietic stem cell transplantation.
  • the transplantation may in turn re-constitute, for example, a population of cells depleted during the process of eradicating autoimmune cells.
  • inflammatory demyelinating polyneuropathy Crohn's disease, cicatrical pemphigoid, coeliac sprue-dermatitis herpetiformis, cold agglutinin disease, CREST syndrome, Degos disease, discoid lupus, dysautonomia, endometriosis, essential mixed cryoglobulinemia, fibromyalgia-fibromyositis, Goodpasture' s syndrome, Grave's disease, Guillain-Barre syndrome (GBS), Hashimoto' s thyroiditis, Hidradenitis suppurativa, idiopathic and/or acute thrombocytopenic purpura, idiopathic pulmonary fibrosis, IgA neuropathy, interstitial cystitis, juvenile arthritis, Kawasaki's disease, lichen planus, Lyme disease, Meniere disease, mixed connective tissue disease (MCTD), myasthenia gravis, neuromyotonia, opsoclonus
  • Re is H, OH, ORc, ORD, RC, or RD;
  • the ligand or fragment thereof is covalently bound to a cytotoxin, such as a cytotoxin described herein (for example, pseudomonas exotoxin A, deBouganin, diphtheria toxin, an amatoxin, such as a- amanitin, saporin, maytansine, a maytansinoid, an auristatin, an anthracycline, a calicheamicin, irinotecan, SN-38, a duocarmycin, a pyrrolobenzodiazepine, a pyrrolobenzodiazepine dimer, an indolinobenzodiazepine, and an cytotoxin, such as a cytotoxin described herein (for example, pseudomonas exotoxin A, deBouganin, diphtheria toxin, an amatoxin, such as a- amanitin, saporin, maytansine, a may
  • Ri is H, OH, or ORA
  • RD is optionally substituted alkyl (e.g ., C1 -C6 alkyl), optionally substituted heteroalkyl (e.g. , C1 -C6 heteroalkyl), optionally substituted alkenyl (e.g. , C2-C6 alkenyl), optionally substituted heteroalkenyl (e.g. , C2-C6 heteroalkenyl), optionally substituted alkynyl (e.g. , C2-C6 alkynyl), optionally substituted heteroalkynyl (e.g. , C2- C6 heteroalkynyl), optionally substituted cycloalkyl, optionally substituted
  • mAb monoclonal antibody
  • mAb monoclonal antibody
  • Fab and F(ab')2 fragments refer to antibody fragments that lack the Fc fragment of an intact antibody. Examples of these antibody fragments are described herein.
  • heteroalkyl refers to a straight or branched-chain alkyl group having, for example, from 1 to 20 carbon atoms in the chain, and further containing one or more heteroatoms (e.g., oxygen, nitrogen, or sulfur, among others) in the chain.
  • heteroalkylene refers to a straight- or branched- chain divalent heteroalkyl group.
  • the divalent positions may be on the same or different atoms within the heteroalkyl chain.
  • the divalent positions may be one or more heteroatoms.
  • Exemplary antigen- binding fragments of the foregoing antibodies include a dual-variable immunoglobulin domain, a single-chain Fv molecule (scFv), a diabody, a triabody, a nanobody, an antibody-like protein scaffold, a Fv fragment, a Fab fragment, a F(ab')2 molecule, and a tandem di-scFv, among others.
  • scFv single-chain Fv molecule
  • RA and RB together with the oxygen atoms to which they are bound, combine to form an optionally substituted 5-membered heterocyclolalkyl group
  • R? is H, OH, ORc, ORD, RC, or RD;
  • Rc is -L-Z
  • RA and RB together with the oxygen atoms to which they are bound, combine to form an optionally substituted 5-membered heterocyclolalkyl group
  • R? is H, OH, ORc, ORD, RC, or RD;
  • Am is represented by formula (IA) or formula (IB), wherein Ri is H, OH, ORA, or ORc;
  • R 9 is H or OH ;
  • Linkers useful in conjunction with the antibody-drug and ligand-drug conjugates described herein include, without limitation, linkers containing chemical moieties formed by coupling reactions as depicted in Table 1 , below. Curved lines designate points of attachment to the antibody, antigen-binding fragment, or ligand and the cytotoxic molecule, respectively.
  • Hematopoietic stem cells are additionally capable of self-renewal, and can thus give rise to daughter cells that have equivalent potential as the mother cell, and also feature the capacity to be reintroduced into a transplant recipient whereupon they home to the hematopoietic stem cell niche and re-establish productive and sustained hematopoiesis.
  • Additional diseases that can be treated with the compositions and methods described herein include, without limitation, adenosine deaminase deficiency and severe combined immunodeficiency, hyper immunoglobulin M syndrome, Chediak- Higashi disease, hereditary lymphohistiocytosis, osteopetrosis, osteogenesis imperfecta, storage diseases, thalassemia major, systemic sclerosis, systemic lupus erythematosus, multiple sclerosis, and juvenile rheumatoid arthritis.
  • a physician of skill in the art can withdraw a blood sample from the patient at various time points during conditioning therapy and determine the extent of endogenous hematopoietic stem cell reduction by conducting a FACS analysis to elucidate the relative concentrations of hematopoietic stem cells in the sample using antibodies that bind to hematopoietic stem cell marker antigens.
  • the physician may conclude the conditioning therapy, and may begin preparing the patient for hematopoietic stem cell transplant therapy.
  • the anti-CD1 17 (e.g., anti-GNNK+ CD1 17) antibody, antigen-binding fragment thereof, or drug-antibody conjugate can be administered to the patient in an aqueous solution containing one or more pharmaceutically acceptable excipients, such as a viscosity-modifying agent.
  • the aqueous solution may be sterilized using techniques described herein or known in the art.
  • the antibody, antigen-binding fragment thereof, or drug-antibody conjugate can be administered to the patient at a dosage of, for example, from 0.001 mg/kg to 100 mg/kg prior to administration of a hematopoietic stem cell graft to the patient.
  • monoclonal anti-CD1 17 antibodies or isotype controls were either bound to Fab fragments conjugated to saporin or were directly conjugated to saporin, monomethyl auristatin E (MMAE), monomethyl auristatin F (MMAF), or a-amanitin.
  • MMAE monomethyl auristatin E
  • MMAF monomethyl auristatin F

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
PCT/US2017/038158 2016-06-17 2017-06-19 Compositions and methods for the depletion of cd117+cells Ceased WO2017219029A2 (en)

Priority Applications (13)

Application Number Priority Date Filing Date Title
EA201892659A EA201892659A1 (ru) 2017-01-20 2017-06-19 Композиции и способы истощения cd117+ клеток
CN201780050606.8A CN109661400A (zh) 2016-06-17 2017-06-19 用于耗尽cd117+细胞的组合物和方法
JP2019518186A JP7062647B2 (ja) 2016-06-17 2017-06-19 Ｃｄ１１７＋細胞を枯渇させるための組成物及び方法
MX2018015684A MX2018015684A (es) 2016-06-17 2017-06-19 Composiciones y metodos para el agotamiento de celulas cd117.
IL303455A IL303455A (en) 2016-06-17 2017-06-19 Compositions and methods for the depletion of cd117+cells
IL263744A IL263744B2 (en) 2016-06-17 2017-06-19 Compositions and methods for the depletion of cd117 plus cells
SG11201811290VA SG11201811290VA (en) 2016-06-17 2017-06-19 Compositions and methods for the depletion of cd117+cells
EP17814263.4A EP3472178A4 (en) 2016-06-17 2017-06-19 COMPOSITION AND METHOD FOR DEPLYING CD117 + CELLS
KR1020237014621A KR20230066647A (ko) 2016-06-17 2017-06-19 Cd117+ 세포의 고갈을 위한 조성물 및 방법
CA3028134A CA3028134A1 (en) 2016-06-17 2017-06-19 Compositions and methods for the depletion of cd117+ cells
BR112018076306-3A BR112018076306A2 (pt) 2016-06-17 2017-06-19 composições e métodos para a supressão de células cd117+
KR1020197001540A KR20190038537A (ko) 2016-06-17 2017-06-19 Cd117+ 세포의 고갈을 위한 조성물 및 방법
JP2022069352A JP2022106807A (ja) 2016-06-17 2022-04-20 Ｃｄ１１７＋細胞を枯渇させるための組成物及び方法

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201662351725P 2016-06-17 2016-06-17
US62/351,725 2016-06-17
US201662437729P 2016-12-22 2016-12-22
US62/437,729 2016-12-22
US201762448782P 2017-01-20 2017-01-20
US62/448,782 2017-01-20

Publications (3)

Publication Number Publication Date
WO2017219029A2 true WO2017219029A2 (en) 2017-12-21
WO2017219029A3 WO2017219029A3 (en) 2018-01-25
WO2017219029A8 WO2017219029A8 (en) 2019-01-17

Family

ID=60119017

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2017/038158 Ceased WO2017219029A2 (en) 2016-06-17 2017-06-19 Compositions and methods for the depletion of cd117+cells

Country Status (13)

Country Link
US (3) US10111966B2 (enExample)
EP (1) EP3472178A4 (enExample)
JP (2) JP7062647B2 (enExample)
KR (2) KR20230066647A (enExample)
CN (1) CN109661400A (enExample)
AU (4) AU2017204125B1 (enExample)
BR (1) BR112018076306A2 (enExample)
CA (1) CA3028134A1 (enExample)
IL (2) IL303455A (enExample)
MA (1) MA45408A (enExample)
MX (1) MX2018015684A (enExample)
SG (2) SG11201811290VA (enExample)
WO (1) WO2017219029A2 (enExample)

Cited By (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018116178A1 (en) * 2016-12-21 2018-06-28 Novartis Ag Antibody drug conjugates for ablating hematopoietic stem cells
WO2018115466A1 (en) * 2016-12-23 2018-06-28 Heidelberg Pharma Research Gmbh Amanitin antibody conjugates
WO2018183613A1 (en) * 2017-03-31 2018-10-04 The Children's Medical Center Corporation Antibody-mediated conditioning with immunosuppression to enable allogeneic transplantation
WO2019018383A1 (en) 2017-07-18 2019-01-24 Calimmune, Inc. COMPOSITIONS AND METHODS FOR TREATING BETA-HEMOGLOBINOPATHIES
WO2020037009A1 (en) * 2018-08-13 2020-02-20 Flagship Pioneering Innovations V, Inc. Conjugates and methods of using the same
WO2019244082A3 (en) * 2018-06-20 2020-03-05 Novartis Ag Antibody drug conjugates for ablating hematopoietic stem cells
WO2020139796A1 (en) 2018-12-23 2020-07-02 Csl Behring L.L.C. Haematopoietic stem cell-gene therapy for wiskott-aldrich syndrome
WO2019234694A3 (en) * 2018-06-07 2020-09-03 Magenta Therapeutics, Inc. Therapeutic methods using antibody drug conjugates (adcs)
WO2020219964A1 (en) * 2019-04-24 2020-10-29 Magenta Therapeutics, Inc. Conditioning methods for gene therapy
WO2020219775A1 (en) * 2019-04-24 2020-10-29 Magenta Therapeutics, Inc. Anti-cd117 antibody-drug conjugates and uses thereof
WO2020219778A3 (en) * 2019-04-24 2020-12-03 Magenta Therapeutics, Inc. Anti-cd117 antibody-drug conjugates and uses thereof
US10882915B2 (en) 2017-10-24 2021-01-05 Magenta Therapeutics, Inc. Compositions and methods for the depletion of CD117+ cells
US10899843B2 (en) 2017-10-24 2021-01-26 Magenta Therapeutics, Inc. Compositions and methods for the depletion of CD117+ cells
CN112739339A (zh) * 2018-07-23 2021-04-30 美真达治疗公司 抗cd137抗体药物缀合物(adc)在同种异体细胞疗法中的用途
JP2021518847A (ja) * 2017-09-08 2021-08-05 四川百利薬業有限責任公司Ｓｉｃｈｕａｎ Ｂａｉｌｉ Ｐｈａｒｍ Ｃｏ．， Ｌｔｄ． アマニチン類抗体複合物
JP2022507962A (ja) * 2018-11-26 2022-01-18 フォーティ セブン， インコーポレイテッド ｃ－Ｋｉｔに対するヒト化抗体
EP3959242A4 (en) * 2019-04-24 2023-09-13 Magenta Therapeutics, Inc. ANTRACYCLINE ANTIBODY-DRUG CONJUGATES AND THEIR USES
EP4022051A4 (en) * 2019-08-29 2024-01-10 Beam Therapeutics Inc. COMPOSITIONS AND METHODS FOR NON-TOXIC CONDITIONING
WO2024121632A1 (en) 2022-12-09 2024-06-13 Crispr Therapeutics Ag Use of anti-cd117 antibody drug conjugate (adc)
US12133884B2 (en) 2018-05-11 2024-11-05 Beam Therapeutics Inc. Methods of substituting pathogenic amino acids using programmable base editor systems

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109641051A (zh) 2016-06-17 2019-04-16 美真达治疗公司 用于耗尽细胞的组合物和方法
SG11201906319XA (en) 2017-01-20 2019-08-27 Magenta Therapeutics Inc Compositions and methods for the depletion of cd137+ cells
IL301075B2 (en) 2017-01-30 2024-05-01 Univ Leland Stanford Junior A genotoxic matching regimen for stem cell transplantation
AU2018374283B2 (en) * 2017-11-29 2025-09-18 Magenta Therapeutics, Inc. Compositions and methods for the depletion of CD5+ cells
AU2019374055B2 (en) * 2018-10-30 2026-06-11 Regeneron Pharmaceuticals, Inc. Methods for allogeneic hematopoietic stem cell transplantation
JP2022529727A (ja) * 2019-04-24 2022-06-23 マジェンタ セラピューティクス インコーポレイテッド Ａｎｔｉ－ｃｄ１１７ とその使用
WO2021007266A1 (en) * 2019-07-09 2021-01-14 Hemogenyx Llc Method of eliminating hematopoietic stem cells/hematopoietic progenitors (hsc/hp) in a patient using bi-specific antibodies
WO2022081828A1 (en) * 2020-10-16 2022-04-21 The Board Of Trustees Of The Leland Stanford Junior University Hematopoietic stem cell engraftment with a combination of agents
US20240000847A1 (en) * 2020-11-06 2024-01-04 Bluebird Bio, Inc. Methods
US20240082416A1 (en) * 2020-12-08 2024-03-14 The University Of British Columbia Amatoxin analogs and uses thereof
CN113485489B (zh) * 2021-06-18 2022-05-10 淮阴工学院 一种orc系统蒸发器出口温度的调控方法
WO2024102954A1 (en) 2022-11-10 2024-05-16 Massachusetts Institute Of Technology Activation induced clipping system (aics)
WO2025235862A1 (en) 2024-05-10 2025-11-13 Inndura Therapeutics Inc. A modified immune cell receptor comprising a target-binding domain and the extracellular domain of cd16a

Family Cites Families (129)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5451575A (en) 1988-02-19 1995-09-19 J. W. Broadbent Nominees Pty., Ltd. Method of treating liver dysfunction with 24-R scymnol
WO1990009799A1 (en) 1989-02-23 1990-09-07 Colorado State University Research Foundation GnRH ANALOGS FOR DESTROYING GONADOTROPHS
US5786457A (en) 1989-02-23 1998-07-28 Colorado State University Research Foundation Hormone-nuclease compounds and method for regulating hormone related diseases
US5273738A (en) 1990-03-03 1993-12-28 Fred Hutchinson Cancer Research Center Radiation delivery to lymphoid and marrow tissues
US5367057A (en) 1991-04-02 1994-11-22 The Trustees Of Princeton University Tyrosine kinase receptor flk-2 and fragments thereof
DK0578774T3 (da) 1991-04-05 1999-04-26 Univ Washington Monoklonale antistoffer mod stamcellefaktor-receptorer
AU3665293A (en) 1992-02-14 1993-09-03 Merck & Co., Inc. Chimeric toxins binding to the GnRH receptor
EP0703990A4 (en) 1993-04-30 1997-09-24 Lxr Biotechnology Inc METHOD FOR DETECTING POTENTIALLY THERAPEUTICALLY EFFECTIVE AGENTS AND CELL LINES THAT CAN BE USED FOR THIS
US6106834A (en) 1993-06-02 2000-08-22 Research Corporation Technologies, Inc. Use of anti-CD45 leukocyte antigen antibodies for immunomodulation
US6024957A (en) 1993-06-02 2000-02-15 Research Corporation Technologies, Inc. Immunomodulators and methods for the prevention and reversal of organ transplant rejection using same
EP1186301B1 (en) 1993-09-08 2006-08-16 Imclone Systems, Inc. Monoclonal antibodies that recognize flk-2 receptors and the isolation of primitive hematopoietic stem cell populations
GB2282812A (en) 1993-10-15 1995-04-19 Merck & Co Inc Cytotoxic/receptor ligand conjugates linked via lysine radicals
GB9323199D0 (en) 1993-11-10 1994-01-05 Falkenberg J H F Leukaemia treatment
DE4343261C2 (de) 1993-12-17 1995-11-02 Susanne Holzer Verfahren zur präparativen Herstellung von Ausgangsstoffen für Immunoassays und Bioassays
US5635388A (en) 1994-04-04 1997-06-03 Genentech, Inc. Agonist antibodies against the flk2/flt3 receptor and uses thereof
DE19600589C1 (de) 1996-01-10 1997-01-16 Univ Eberhard Karls Antikörper A3C6E2
DE19608769C1 (de) 1996-03-07 1997-04-10 Univ Eberhard Karls Antikörper BV10A4H2
IL129138A0 (en) 1996-10-11 2000-02-17 Bristol Myers Squibb Co Methods and compositions for immunomodulation
CA2284726A1 (en) 1997-04-11 1998-10-22 G.D. Searle & Co. Antagonistic anti-avb3 integrin antibodies
DE19727814C1 (de) 1997-06-30 1998-10-01 Univ Eberhard Karls Anitkörper 4G8B4B12
DE19808453C2 (de) 1998-02-27 2000-12-14 Gsf Forschungszentrum Umwelt Expressionsvektor zur konditionalen Regulation der Expression der großen Untereinheit der RNA-Polymerase II
US6339062B1 (en) 1998-11-23 2002-01-15 Inkine Pharmaceutical Company, Inc. Retroinverso polypeptides that mimic or inhibit thrombospondin activity
US6831071B2 (en) 1999-04-08 2004-12-14 Pavel Sergeev Synthesis of biologically active compounds in cells
US6159443A (en) 1999-04-29 2000-12-12 Vanderbilt University X-ray guided drug delivery
AUPQ014799A0 (en) 1999-05-04 1999-05-27 Access Pharmaceuticals Australia Pty Limited Amplification of folate-mediated targeting to tumor cells using polymers
AUPQ014699A0 (en) 1999-05-04 1999-05-27 Access Pharmaceuticals Australia Pty Limited Amplification of folate-mediated targeting to tumor cells using nanoparticles
WO2002032955A1 (en) 2000-10-18 2002-04-25 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services. Human gene critical to fertility
EP1349924A2 (en) 2000-11-03 2003-10-08 Dana Farber Cancer Institute Methods and compositions for the diagnosis of cancer susceptibilites and defective dna repair mechanisms and treatment thereof
US20050069538A1 (en) 2003-09-18 2005-03-31 Gregorio Aversa Therapeutic binding molecules
GB0110430D0 (en) 2001-04-27 2001-06-20 Medical Res Council Protein variants and uses thereof
GB0122914D0 (en) 2001-09-22 2001-11-14 Univ Nottingham Modulation of stat activity
CN1184890C (zh) 2001-10-09 2005-01-19 湖南师范大学 含鹅膏肽毒素基因的苏云金杆菌工程菌双效杀虫剂
US7265212B2 (en) 2001-12-03 2007-09-04 Amgen Fremont Inc. Anti-CD45RB antibodies
AR037756A1 (es) 2001-12-17 2004-12-01 Bayer Corp Anticuerpo que inhibe la actividad del factor de las celulas precursoras y su uso para el tratamiento del asma.
US7183385B2 (en) 2002-02-20 2007-02-27 Cell Signaling Technology, Inc. Phospho-specific antibodies to Flt3 and uses thereof
US20030232369A1 (en) 2002-04-17 2003-12-18 Bushnell David A. Molecular structure of RNA polymerase II
DE10219866A1 (de) 2002-05-03 2003-11-20 Isolde Riede-Kainrath Tumorprävention und Therapie durch Modifikation von "switch"-Genen oder RNA-Polymerase II-Aktivität
AU2003245752A1 (en) * 2002-06-28 2004-01-19 Bio Transplant, Inc. Process for promoting graft acceptance by depletion of hematopoietic stem cells
AU2002953073A0 (en) 2002-11-21 2003-01-16 Access Pharmaceuticals Australia Pty Limited Amplification of biotin-mediated targeting
US7166691B2 (en) 2002-12-20 2007-01-23 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Saposin C and receptors as targets for treatment of benign and malignant disorders
WO2006002064A2 (en) 2004-06-14 2006-01-05 Aerovance, Inc. Antibody inhibiting stem cell factor activity and use for treatment of asthma
US20060014197A1 (en) 2004-07-15 2006-01-19 Wisconsin Alumni Research Foundation In vivo screening methods for identifying inhibitors of RNA polymerases
JP5704785B2 (ja) 2004-07-19 2015-04-22 ザ・ジョンズ・ホプキンス・ユニバーシティ 免疫抑制のためのｆｌｔ３阻害剤
EP1661584A1 (en) 2004-11-26 2006-05-31 Heinz Dr. Faulstich Use of conjugates of amatoxins and phallotoxins with macromolecules for cancer and inflammation therapy
CA2609751A1 (en) 2005-05-24 2006-11-30 Dana Farber Cancer Institute, Inc. Compositions and methods for the treatment of cancer
US20110014151A1 (en) 2006-01-11 2011-01-20 Biotech Igg Ab Macromolecule conjugate
WO2007087453A2 (en) 2006-01-27 2007-08-02 Cellerant Therapeutics, Inc. Compositions and methods for treating haematological proliferative disorders
CA2649114A1 (en) 2006-04-12 2007-10-25 Crosslink Genetics Corporation Compositions and methods for modulating gene expression
TWI395754B (zh) 2006-04-24 2013-05-11 Amgen Inc 人類化之ｃ-ｋｉｔ抗體
ATE521366T1 (de) 2006-05-27 2011-09-15 Faulstich Heinz Dr Anwendung von amatoxin-konjugaten und phallotoxin-konjugaten mit makromolekülen zur krebstherapie und therapie von entzündungen
EP3255061B1 (en) * 2006-11-03 2021-06-16 The Board of Trustees of the Leland Stanford Junior University Selective immunodepletion of endogenous stem cell niche for engraftment
US20100093008A1 (en) 2007-03-02 2010-04-15 Cell Signaling Technology, Inc. Phospho-specific antibodies to flt3 (tyr969) and uses thereof
BRPI0812970A2 (pt) 2007-06-25 2019-09-24 Endocyte Inc conjugados contendo espaçadores hidrofílicos
WO2009011893A2 (en) 2007-07-17 2009-01-22 Combinatorx, Incorporated Treatments of b-cell proliferative disorders
US9518097B2 (en) 2007-11-09 2016-12-13 Board Of Trustees Of Michigan State University Identification and use of genes encoding amatoxin and phallotoxin
AR071891A1 (es) 2008-05-30 2010-07-21 Imclone Llc Anticuerpos humanos anti-flt3 (receptor tirosina cinasa 3 tipo fms humano)
WO2010045218A1 (en) 2008-10-13 2010-04-22 Board Of Regents, The University Of Texas System Molecular clock mechanism of hybrid vigor
US8940705B2 (en) 2009-01-09 2015-01-27 The Regents Of The University Of California Method of treating disease and selectively modulating transcriptional regulation by a glucocorticoid receptor by administering aclacinomycin and dexamethasone
MX2011010469A (es) 2009-04-08 2012-03-14 Deutsches Krebsforsch Radicales de enlace al objetivo, armados con amatoxina para el tratamiento del cancer.
EP3192529B1 (en) * 2009-04-08 2020-03-25 Faulstich, Heinz, Dr. Amatoxin-armed therapeutic cell surface binding components designed for tumour therapy
WO2010136508A2 (en) * 2009-05-28 2010-12-02 Glaxo Group Limited Stem cell targeting
EP2473187A4 (en) * 2009-08-31 2015-09-16 Immunomedics Inc COMPOSITIONS AND METHODS FOR USE OF IMMUNOXINS WITH RANPIRNASE (RAP) WITH HIGH CYTOTOXIC ACTIVITY
US8518405B2 (en) 2009-10-08 2013-08-27 The University Of North Carolina At Charlotte Tumor specific antibodies and uses therefor
US20130023051A1 (en) 2009-12-21 2013-01-24 Keygene N.V. Techniques for transfecting protoplasts
ES2573642T3 (es) 2009-12-23 2016-06-09 Synimmune Gmbh Anticuerpos anti-FLT3 y métodos de usar los mismos
US9109227B2 (en) 2010-01-05 2015-08-18 Institut National De La Sante Et De La Recherche Medicale (Inserm) FLT3 receptor antagonists for the treatment or the prevention of pain disorders
KR20110085038A (ko) 2010-01-19 2011-07-27 울산대학교 산학협력단 항 ｃｄ137-항체 및 독소 결합물을 이용한 ｃｄ137 양성세포의 제거방법
CN101861796B (zh) 2010-05-18 2012-02-15 四川大学 一种利用有色稻米发酵废糟培养豹斑毒鹅膏的方法
CA3032186C (en) 2010-07-13 2022-04-26 Council on Postsecondary Education, State of Rhode Island and Providence Plantations Environmentally sensitive composition comprising a ph triggered peptide and uses thereof
NZ729044A (en) 2010-09-09 2020-07-31 Pfizer 4-1bb binding molecules
ES2402254T3 (es) 2010-09-30 2013-04-30 Heidelberg Pharma Ag Conjugados de amatoxinas con ligadores mejorados
WO2012084895A2 (en) 2010-12-20 2012-06-28 Universiteit Gent Crystal structure of flt3 ligand-receptor complex
CN102526034B (zh) 2010-12-24 2015-02-25 四川大学华西医院 恒河猴爆发性肝功能衰竭模型的建立
US20120189633A1 (en) 2011-01-26 2012-07-26 Kolltan Pharmaceuticals, Inc. Anti-kit antibodies and uses thereof
EP2497499A1 (en) 2011-03-10 2012-09-12 Heidelberg Pharma GmbH Amatoxin-conjugates with improved linkages
AR086044A1 (es) * 2011-05-12 2013-11-13 Imclone Llc Anticuerpos que se unen especificamente a un dominio extracelular de c-kit y usos de los mismos
WO2013131927A1 (en) 2012-03-06 2013-09-12 Novartis Ag Combining dna-damaging agents and modulators of actin polymerization for the treatment of cancer
CN104640572B (zh) 2012-05-15 2018-04-27 索伦托医疗有限公司 药物偶联物，偶联方法，及其用途
WO2013192546A1 (en) 2012-06-22 2013-12-27 Cytomx Therapeutics, Inc. Activatable antibodies having non-binding steric moieties and mehtods of using the same
EP2684865A1 (en) * 2012-07-13 2014-01-15 Heidelberg Pharma GmbH Methods for synthesizing amatoxin building block and amatoxins
CN102786586A (zh) 2012-07-20 2012-11-21 包海鹰 玫瑰红鹅膏发酵菌丝体中肽类毒素的发现
EP4063391A1 (en) 2012-07-25 2022-09-28 Celldex Therapeutics, Inc. Anti-kit antibodies and uses thereof
US20150218220A1 (en) 2012-09-12 2015-08-06 Brian Alan MENDELSOHN Amatoxin derivatives and cell-permeable conjugates thereof as inhibitors of rna polymerase
US9670521B2 (en) 2012-09-24 2017-06-06 Medimmune Limited Amino acid derivatives
GB201217296D0 (en) 2012-09-27 2012-11-14 Alta Innovations Ltd Method of treatment and/or prevention
EA201590622A1 (ru) 2012-10-16 2015-10-30 Эндосайт, Инк. Конъюгаты для доставки лекарственного средства, содержащие не встречающиеся в природе аминокислоты, и способы применения
SG11201504920SA (en) 2012-12-27 2015-07-30 Sanofi Sa Anti-lamp1 antibodies and antibody drug conjugates, and uses thereof
EP2774624A1 (en) 2013-03-04 2014-09-10 Heidelberg Pharma GmbH Amatoxin derivatives
MX366978B (es) 2013-03-15 2019-08-01 Novartis Ag Conjugados de anticuerpo - farmaco.
EP2968591A1 (en) * 2013-03-15 2016-01-20 Novartis AG Cell proliferation inhibitors and conjugates thereof
CN110251683A (zh) 2013-06-24 2019-09-20 Abl生物公司 具有改进的稳定性的抗体-药物缀合物及其用途
WO2015006554A1 (en) 2013-07-10 2015-01-15 The Regents Of The University Of Michigan Therapeutic antibodies and uses thereof
FR3008408B1 (fr) * 2013-07-11 2018-03-09 Mc Saf Nouveaux conjugues anticorps-medicament et leur utilisation en therapie
EP3020809B1 (en) 2013-07-12 2019-09-04 Ishihara Sangyo Kaisha, Ltd. Composition for transferring gene to cell
WO2015013429A1 (en) 2013-07-23 2015-01-29 The Ohio State University Methods and compositions related to single chain antibody fragments that bind to tumor-associated glycoprotein 72 (tag-72)
WO2015050959A1 (en) 2013-10-01 2015-04-09 Yale University Anti-kit antibodies and methods of use thereof
US9932410B2 (en) 2013-11-05 2018-04-03 Inserm (Institut National De La Sante Et De La Recherche Medicale Human neutralizing anti-kit antibodies and uses thereof
CN103627757B (zh) 2013-12-02 2016-04-13 云南大学 提高小豹斑鹅膏菌丝体产毒能力的方法
CN105377304B (zh) * 2014-03-10 2018-05-15 海德堡医药有限责任公司 鹅膏毒肽衍生物
BR112016020065A2 (pt) 2014-03-12 2018-02-20 Novartis Ag sítios específicos para modificar anticorpos para fazer imunoconjugados
US10973920B2 (en) 2014-06-30 2021-04-13 Glykos Finland Oy Saccharide derivative of a toxic payload and antibody conjugates thereof
CA2956161A1 (en) 2014-07-23 2016-01-28 Ohio State Innovation Foundation Methods and compositions related to antibody fragments that bind to tumor-associated glycoprotein 72 (tag-72)
ES2945588T3 (es) * 2014-08-26 2023-07-04 Univ Leland Stanford Junior Injerto de células madre con una combinación de un agente dirigido a las células madre y modulación de señalización inmunoreguladora
WO2016036334A1 (en) 2014-09-03 2016-03-10 Şahi̇n Yücel Voltametric methods to determine alpha-amanitin and phalloidin
US20170224758A1 (en) 2014-10-17 2017-08-10 The Broad Institute, Inc. Compositions and methods of treating muscular dystrophy
EP3215519A1 (en) 2014-11-06 2017-09-13 Novartis AG Amatoxin derivatives and conjugates thereof as inhibitors of rna polymerase
WO2016077505A2 (en) 2014-11-11 2016-05-19 Amunix Operating Inc. Targeted xten conjugate compositions and methods of making same
US20160220687A1 (en) 2015-02-02 2016-08-04 National Guard Health Affairs Metalloproteinase-cleavable alpha-amanitin-dendrimer conjugates and method of treating cancer
KR102672113B1 (ko) 2015-02-16 2024-06-03 론자 리미티드 Cl 및/또는 ch1 돌연변이된 약물 접합용 항체
BR112017018861A2 (pt) 2015-03-04 2018-04-24 Board Of Regents, The Unibersity Of Texas System métodos para tratar câncer mantendo perda hemizigótica de tp53
CA2978631C (en) 2015-03-09 2023-06-27 Agensys, Inc. Antibody drug conjugates (adc) that bind to flt3 proteins
DK3268047T3 (da) 2015-03-09 2024-01-02 Heidelberg Pharma Res Gmbh Amatoxin/antistof-konjugater
US20180318285A1 (en) 2015-03-10 2018-11-08 President And Fellows Of Harvard College Methods for treatment of autism spectrum disorders
EP3273984B1 (en) 2015-03-25 2021-05-05 Children's Hospital Medical Center Use of kit inhibitors to condition subjects for a hematopoietic stem cell (hsc) transplantation
HK1256681A1 (zh) * 2015-04-06 2019-10-04 President And Fellows Of Harvard College 用於非清髓性预处理的组合物和方法
US10683506B2 (en) 2015-04-10 2020-06-16 The Methodist Hospital System CD117 ligand-drug conjugates for targeted cancer therapy
WO2016168471A1 (en) 2015-04-17 2016-10-20 Endocyte, Inc. Dual disulfide drug conjugates
CN104862314B (zh) 2015-05-11 2017-12-01 昆明理工大学 一种与α‑鹅膏毒肽特异结合的核酸适配体及应用
WO2016185403A1 (en) 2015-05-18 2016-11-24 Universidade Do Porto Use of polymyxin as an antidote for intoxications by amatoxins
CA2986699A1 (en) 2015-05-22 2016-12-01 Memorial Sloan Kettering Cancer Center Systems and methods for determining optimum patient-specific antibody dose for tumor targeting
US11384104B2 (en) 2015-06-19 2022-07-12 Centurion Biopharma Corporation Delivery systems for controlled drug release
US10961308B2 (en) 2015-06-29 2021-03-30 The General Hospital Corporation Embigin inhibition for promotion of hematopoietic stem and progenitor cell expansion
WO2017011803A1 (en) 2015-07-16 2017-01-19 Cellerant Therapeutics, Inc. Cysteine-substituted immunoglobulins
GB201601073D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibodies
WO2017023753A1 (en) 2015-07-31 2017-02-09 University Of Florida Research Foundation, Inc. Hematopoietic stem cells in combinatorial therapy with immune checkpoint inhibitors against cancer
CN105177009B (zh) 2015-08-10 2018-05-25 昆明理工大学 一种与α-鹅膏毒肽特异结合的核酸适配体及应用
HK1259487A1 (zh) 2016-02-04 2019-11-29 Hangzhou Dac Biotech Co. Ltd. 特定的共轭连接子，特定的免疫共轭物，制造和使用这些共轭物的方法
CN106153768B (zh) 2016-06-30 2019-01-01 佛山科学技术学院 鹅膏毒肽分子印迹材料用于α-amanitin和β-amanitin的固相萃取方法
CN117653740A (zh) * 2016-12-21 2024-03-08 诺华股份有限公司 用于消融造血干细胞的抗体药物缀合物

Cited By (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017383458B2 (en) * 2016-12-21 2021-04-29 Novartis Ag Antibody drug conjugates for ablating hematopoietic stem cells
US12171839B2 (en) 2016-12-21 2024-12-24 Novartis Ag Antibody drug conjugates for ablating hematopoietic stem cells
WO2018116178A1 (en) * 2016-12-21 2018-06-28 Novartis Ag Antibody drug conjugates for ablating hematopoietic stem cells
US11357864B2 (en) 2016-12-21 2022-06-14 Novartis Ag Antibody drug conjugates for ablating hematopoietic stem cells
AU2017383458C1 (en) * 2016-12-21 2021-08-12 Novartis Ag Antibody drug conjugates for ablating hematopoietic stem cells
WO2018115466A1 (en) * 2016-12-23 2018-06-28 Heidelberg Pharma Research Gmbh Amanitin antibody conjugates
US11446388B2 (en) 2016-12-23 2022-09-20 Heidelberg Pharma Research Gmbh Amanitin antibody conjugates
WO2018183613A1 (en) * 2017-03-31 2018-10-04 The Children's Medical Center Corporation Antibody-mediated conditioning with immunosuppression to enable allogeneic transplantation
US12485186B2 (en) 2017-03-31 2025-12-02 The Children's Medical Center Corporation Antibody-mediated conditioning with immunosuppression to enable allogeneic transplantation
WO2019018383A1 (en) 2017-07-18 2019-01-24 Calimmune, Inc. COMPOSITIONS AND METHODS FOR TREATING BETA-HEMOGLOBINOPATHIES
JP7296396B2 (ja) 2017-09-08 2023-06-22 バイリ－バイオ（チェンドゥ）ファーマスーティカル シーオー．，エルティーディー． アマニチン類抗体複合物
AU2018329066B2 (en) * 2017-09-08 2022-02-17 Systimmune, Inc. Amanitin antibody conjugate
JP2021518847A (ja) * 2017-09-08 2021-08-05 四川百利薬業有限責任公司Ｓｉｃｈｕａｎ Ｂａｉｌｉ Ｐｈａｒｍ Ｃｏ．， Ｌｔｄ． アマニチン類抗体複合物
US11958908B2 (en) 2017-10-24 2024-04-16 Crispr Therapeutics Ag Compositions and methods for the depletion of CD117+ cells
US10899843B2 (en) 2017-10-24 2021-01-26 Magenta Therapeutics, Inc. Compositions and methods for the depletion of CD117+ cells
US11572411B2 (en) 2017-10-24 2023-02-07 Magenta Therapeutics, Inc. Anti-CD117 antibodies and conjugates
US10882915B2 (en) 2017-10-24 2021-01-05 Magenta Therapeutics, Inc. Compositions and methods for the depletion of CD117+ cells
US12133884B2 (en) 2018-05-11 2024-11-05 Beam Therapeutics Inc. Methods of substituting pathogenic amino acids using programmable base editor systems
JP2021526525A (ja) * 2018-06-07 2021-10-07 マジェンタ セラピューティクス インコーポレイテッドＭａｇｅｎｔａ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． 抗体薬物コンジュゲート（ａｄｃｓ）を用いた治療方法
CN112566671A (zh) * 2018-06-07 2021-03-26 美真达治疗公司 使用抗体药物缀合物(adc)的治疗方法
WO2019234694A3 (en) * 2018-06-07 2020-09-03 Magenta Therapeutics, Inc. Therapeutic methods using antibody drug conjugates (adcs)
WO2019244082A3 (en) * 2018-06-20 2020-03-05 Novartis Ag Antibody drug conjugates for ablating hematopoietic stem cells
CN112437675A (zh) * 2018-06-20 2021-03-02 诺华股份有限公司 用于消融造血干细胞的抗体药物缀合物
CN112739339A (zh) * 2018-07-23 2021-04-30 美真达治疗公司 抗cd137抗体药物缀合物(adc)在同种异体细胞疗法中的用途
WO2020037009A1 (en) * 2018-08-13 2020-02-20 Flagship Pioneering Innovations V, Inc. Conjugates and methods of using the same
US11998610B2 (en) 2018-08-13 2024-06-04 Flagship Pioneering Innovations V, Inc. Conjugates and methods of using the same
JP2022507962A (ja) * 2018-11-26 2022-01-18 フォーティ セブン， インコーポレイテッド ｃ－Ｋｉｔに対するヒト化抗体
JP7166457B2 (ja) 2018-11-26 2022-11-07 フォーティ セブン， インコーポレイテッド ｃ－Ｋｉｔに対するヒト化抗体
US12091458B2 (en) 2018-11-26 2024-09-17 Forty Seven, Inc. Humanized antibodies against c-Kit
WO2020139796A1 (en) 2018-12-23 2020-07-02 Csl Behring L.L.C. Haematopoietic stem cell-gene therapy for wiskott-aldrich syndrome
WO2020219964A1 (en) * 2019-04-24 2020-10-29 Magenta Therapeutics, Inc. Conditioning methods for gene therapy
EP3959242A4 (en) * 2019-04-24 2023-09-13 Magenta Therapeutics, Inc. ANTRACYCLINE ANTIBODY-DRUG CONJUGATES AND THEIR USES
EP3958899A4 (en) * 2019-04-24 2023-08-02 Magenta Therapeutics, Inc. ANTI-CD117 ANTIBODY-DRUG CONJUGATES AND THEIR USES
US20220175946A1 (en) * 2019-04-24 2022-06-09 Magenta Therapeutics, Inc. Conditioning methods for gene therapy
WO2020219775A1 (en) * 2019-04-24 2020-10-29 Magenta Therapeutics, Inc. Anti-cd117 antibody-drug conjugates and uses thereof
WO2020219778A3 (en) * 2019-04-24 2020-12-03 Magenta Therapeutics, Inc. Anti-cd117 antibody-drug conjugates and uses thereof
EP4022051A4 (en) * 2019-08-29 2024-01-10 Beam Therapeutics Inc. COMPOSITIONS AND METHODS FOR NON-TOXIC CONDITIONING
WO2024121632A1 (en) 2022-12-09 2024-06-13 Crispr Therapeutics Ag Use of anti-cd117 antibody drug conjugate (adc)

Also Published As

Publication number Publication date
MA45408A (fr) 2019-04-24
AU2018200503B2 (en) 2020-03-05
SG11201811290VA (en) 2019-01-30
JP7062647B2 (ja) 2022-05-06
BR112018076306A2 (pt) 2019-03-26
JP2022106807A (ja) 2022-07-20
AU2017204125B1 (en) 2017-10-26
KR20230066647A (ko) 2023-05-16
EP3472178A4 (en) 2020-02-19
WO2017219029A3 (en) 2018-01-25
US20170360954A1 (en) 2017-12-21
AU2022202233A1 (en) 2022-04-21
AU2018200503C1 (en) 2020-08-27
IL263744B2 (en) 2023-11-01
WO2017219029A8 (en) 2019-01-17
EP3472178A2 (en) 2019-04-24
CA3028134A1 (en) 2017-12-21
IL263744A (en) 2019-01-31
US20210162063A1 (en) 2021-06-03
US10111966B2 (en) 2018-10-30
SG10202100726XA (en) 2021-02-25
IL303455A (en) 2023-08-01
IL263744B1 (en) 2023-07-01
CN109661400A (zh) 2019-04-19
KR20190038537A (ko) 2019-04-08
US20190134217A1 (en) 2019-05-09
AU2020201138A1 (en) 2020-03-05
AU2018200503A1 (en) 2018-02-15
JP2019522680A (ja) 2019-08-15
MX2018015684A (es) 2019-08-29

Similar Documents

Publication Publication Date Title
US20240408168A1 (en) Compositions and methods for the depletion of cells
AU2018200503C1 (en) Compositions and methods for the depletion of cd117+ cells
US20250082767A1 (en) Compositions and methods for the depletion of cd5+ cells
TWI825007B (zh) 用於cd137＋細胞耗盡（depletion）之組合物及方法
EP3717519A1 (en) Compositions and methods for the depletion of cd2+ cells
CA3049501C (en) Compositions and methods for the depletion of cd137+ cells

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17814263

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2019518186

Country of ref document: JP

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 3028134

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 122022027034

Country of ref document: BR

NENP Non-entry into the national phase

Ref country code: DE

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112018076306

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 20197001540

Country of ref document: KR

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2017814263

Country of ref document: EP

Effective date: 20190117

ENP Entry into the national phase

Ref document number: 112018076306

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20181217

WWW Wipo information: withdrawn in national office

Ref document number: 303455

Country of ref document: IL